IL315802A - Liquid formulations of ivermectin compositions and use in gelatin dosage forms - Google Patents
Liquid formulations of ivermectin compositions and use in gelatin dosage formsInfo
- Publication number
- IL315802A IL315802A IL315802A IL31580224A IL315802A IL 315802 A IL315802 A IL 315802A IL 315802 A IL315802 A IL 315802A IL 31580224 A IL31580224 A IL 31580224A IL 315802 A IL315802 A IL 315802A
- Authority
- IL
- Israel
- Prior art keywords
- dosage forms
- liquid formulations
- gelatin dosage
- ivermectin
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263322267P | 2022-03-22 | 2022-03-22 | |
| PCT/US2023/064796 WO2023183831A1 (en) | 2022-03-22 | 2023-03-22 | Liquid formulations of ivermectin compositions and use in gelatin dosage forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315802A true IL315802A (en) | 2024-11-01 |
Family
ID=88102199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315802A IL315802A (en) | 2022-03-22 | 2023-03-22 | Liquid formulations of ivermectin compositions and use in gelatin dosage forms |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250195551A1 (en) |
| EP (1) | EP4496576A4 (en) |
| JP (1) | JP2025512795A (en) |
| CN (1) | CN119255808A (en) |
| CA (1) | CA3246159A1 (en) |
| IL (1) | IL315802A (en) |
| WO (1) | WO2023183831A1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016201743B2 (en) * | 2010-05-12 | 2017-10-19 | Boehringer Ingelheim Animal Health USA Inc. | Injectable parasiticidal formulations of levamisole and macrocyclic lactones |
| PL3172964T3 (en) * | 2011-09-12 | 2021-03-08 | Boehringer Ingelheim Animal Health USA Inc. | Antiparasitic compositions containing an isoxazoline active ingredient, method and uses thereof |
| NZ630169A (en) * | 2013-02-27 | 2017-07-28 | Laurie Robert Batt | Anhydrous transdermal formulations |
| CN104706584A (en) * | 2013-12-16 | 2015-06-17 | 天津迈迪瑞康生物医药科技有限公司 | Ivermectin fat emulsion concentrated solution, preparation method and application thereof |
| WO2021138564A1 (en) * | 2019-12-31 | 2021-07-08 | Cure Pharmaceutical Holding Corp. | Oral dissolvable film and method of manufacturing and using the same |
| CN115361944A (en) * | 2020-01-10 | 2022-11-18 | 均衡生物制药私人有限责任公司 | Treatment of neurological disorders with avermectins |
| US11077134B1 (en) * | 2020-11-10 | 2021-08-03 | Mountain Valley Md Inc | Water dissolvable macrocyclic lactone cyclodextrin complexes |
-
2023
- 2023-03-22 US US18/849,392 patent/US20250195551A1/en active Pending
- 2023-03-22 CN CN202380042031.0A patent/CN119255808A/en active Pending
- 2023-03-22 JP JP2024556381A patent/JP2025512795A/en active Pending
- 2023-03-22 EP EP23775865.1A patent/EP4496576A4/en active Pending
- 2023-03-22 IL IL315802A patent/IL315802A/en unknown
- 2023-03-22 CA CA3246159A patent/CA3246159A1/en active Pending
- 2023-03-22 WO PCT/US2023/064796 patent/WO2023183831A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023183831A1 (en) | 2023-09-28 |
| CN119255808A (en) | 2025-01-03 |
| JP2025512795A (en) | 2025-04-22 |
| EP4496576A1 (en) | 2025-01-29 |
| CA3246159A1 (en) | 2023-09-28 |
| EP4496576A4 (en) | 2026-03-11 |
| US20250195551A1 (en) | 2025-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR026916A1 (en) | PHARMACEUTICAL COMBINATIONS AND THEIR USE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
| UA102478C2 (en) | Capsule composition | |
| DK1368004T3 (en) | Mucoadhesive dispersible pharmaceutical preparation for administration of active agent in veterinary and human medicine | |
| NO20030897L (en) | Process for the preparation of pharmaceutical compositions for use with wet gelatin formulations | |
| IL316049A (en) | Pharmaceutical compositions of mosunetuzumab and methods of use | |
| IL316170A (en) | Pharmaceutical compositions of therapeutic proteins and methods of use | |
| ES2865254T3 (en) | Compositions for the treatment of atrophic vaginitis, perimenopausal and postmenopausal dyspareunia and / or oophorectomized women and methods of treatment therewith | |
| ZA202213412B (en) | Pharmaceutical compositions containing enterokine-releasing substances in multiple dosage forms in combination with gelling agents | |
| IL315802A (en) | Liquid formulations of ivermectin compositions and use in gelatin dosage forms | |
| IL272036B1 (en) | Methods and compositions for treating pain using capsaicin | |
| AR048806A1 (en) | USE OF CARIOFILENES IN THE PREPARATION OF MEDICINES AND TREATMENT OF BODY INFLAMMATION AND INFLAMMATORY PAIN AFFECTIONS | |
| JP7186024B2 (en) | External pharmaceutical composition | |
| EP4297777A4 (en) | Oral compositions and use of same in vaccination | |
| Sahu et al. | Formulation and Characterization of Resorcinol Gel | |
| IL326143A (en) | Use of wuling formulation in the preparation of drug for preventing or treating non-alcoholic fatty liver disease | |
| GB2626266B (en) | Oral pharmaceutical compositions of progesterone and estradiol | |
| TR200201556A2 (en) | Pharmaceutical composition containing corticosteroids and nonsteroidal anti-inflammatory | |
| PL4401743T3 (en) | COMPOSITION CONTAINING SODIUM HYALURONATE AND AMINO ACIDS FOR USE IN THE FIELD OF ORTHOPEDICS | |
| WO2020044114A3 (en) | Methotrexate pharmaceutical composition | |
| ES3064824T3 (en) | Pharmaceutical formulations of bictegravir and lenacapavir | |
| EP3856148A4 (en) | PHARMACEUTICAL FORMULATION CONTAINING A TRIGLYCERIDE SELENITE AND A CYTOSTATIC AGENT FOR USE IN THE TREATMENT OF A TUMOR | |
| More et al. | An Overview on Antifungal Drug Therapy | |
| GB202408903D0 (en) | Pharmaceutical compositions and medical uses | |
| Hekmatian et al. | Evaluation of the effect of Elaeagnus angustifolia drug film on gag reflex. | |
| IL314496A (en) | Pharmaceutical composition of anti-trbv9 antibody and use thereof |